A Phase 3 interventional study of 13-valent Pneumoccocal Conjugate Vaccine in Pneumococcal Conjugate Vaccine, sponsored by Pfizer. Completed at 19 sites in 7 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-04-21.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal Conjugate Vaccine in children with Sickle Cell Disease who have already been vaccinated with 23-valent polysaccharide vaccine. The study will measure the amount of antibodies (the proteins that fight off germs) produced by children with Sickle Cell Disease after they have been given the 13-valent pneumococcal vaccine between 6 and less than 18 years of age. They will be given the vaccination twice, each vaccination separated by approximately 6 months.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-valent Pneumoccocal Conjugate Vaccine
2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
Also known as: 13vPnC
Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 1 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 1 and after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with a determinate IgG antibody concentration for the given serotype at both 1 Month After 13vPnC Dose 1 and 1 Month After 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.
Time frame: 1 Month After 13vPnC Dose 1, 1 Month After 13vPnC Dose 2
Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from before 13vPnC Dose 1 and 1 month after 13vPnC Dose 1 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at both the before 13vPnC Dose 1 and 1 month after 13vPnC Dose 1 blood draws. Participants may be represented in more than 1 category.
Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From Before 13vPnC Dose 2 to 1 Month After 13vPnC Dose 2
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 2 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at both the before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.
Time frame: Before 13vPnC Dose 2, 1 month after 13vPnC Dose 2
Ratio of Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 13vPnC Dose 1 to 13vPnC Dose 2
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were computed using the logarithmically transformed assay results for Dose 1 (after Dose 1/before Dose 1) and for Dose 2 (after Dose 2/before Dose 2). CI for the ratio of GMFR (Dose 2/Dose 1) were back transformations of a CI based on the Student t distribution for the mean logarithm of the measures (Dose 2 - Dose 1). Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for given serotype at before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.
Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2, 1 month after 13vPnC Dose 2
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for the specified blood draw. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at specified time point. Participants may be represented in more than 1 category.
Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2, 1 month after 13vPnC Dose 2
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Year After 13vPnC Dose 2
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for the specified blood draw. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here number of participants analyzed signifies the evaluable immunogenicity population at 1-year follow-up and "N" signifies participants with determinate IgG antibody concentration for the given serotype. Participants may be represented in more than 1 category.
Time frame: 1 year after 13vPnC Dose 2
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT)
Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMT and corresponding 2-sided 95% CIs were evaluated. CIs for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate OPA antibody titer for the given serotype at specified time point. Participants may be represented in more than 1 category.
Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2, 1 month after 13vPnC Dose 2
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Year After 13vPnC Dose 2
Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMT and corresponding 2-sided 95% CIs were evaluated. CIs for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here number of participants analyzed signifies the evaluable immunogenicity population at 1-year follow-up and "N" signifies participants with determinate OPA antibody titer for the given serotype. Participants may be represented in more than 1 category.
Time frame: 1 year after 13vPnC Dose 2
Percentage of Participants With Prespecified Local Reactions: 13vPnC Dose 1
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as: Any (redness present or swelling present); Mild (less than \<2.5 centimeters \[cm\] for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged greater than or equal to \[\>=\] 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>=12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>=12 years). Pain was scaled as: Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Here "Number of participants analyzed" signifies the safety population for Dose 1 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified local reaction. Participants may be represented in more than 1 category.
Time frame: Within 7 days after 13vPnC Dose 1
Percentage of Participants With Prespecified Local Reactions: 13vPnC Dose 2
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as: Any (redness present or swelling present); Mild (\<2.5 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>=12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>=12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>=12 years). Pain was scaled as: Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Here number of participants analyzed signifies the safety population for Dose 2 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified local reaction. Participants may be represented in more than 1 category.
Time frame: Within 7 days after 13vPnC Dose 2
Percentage of Participants With Prespecified Systemic Events: 13vPnC Dose 1
Specific systemic events (fever \>=38 degrees Celsius\[C\], vomiting, diarrhea, headache, fatigue, muscle pain, joint pain, use of antipyretic medications) were prompted for each day and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any(symptom present); Mild(did not interfere with activity); Moderate(some interference); Severe(prevented routine daily activity). Vomiting was scaled as: Any(vomiting present); Mild(1-2 times in 24 hours); Moderate(\>2 times in 24 hours); Severe(required intravenous hydration). Diarrhea was scaled as: Any(diarrhea present); Mild(2-3 loose stools in 24 hours);Moderate(4-5 loose stools 24 hours); Severe(\>=6 loose stools in 24 hours). Here number of participants analyzed signifies the safety population for Dose 1 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified systemic event. Participants may be represented in more than 1 category.
Time frame: Within 7 days after 13vPnC Dose 1
Percentage of Participants With Prespecified Systemic Events: 13vPnC Dose 2
Specific systemic events (fever \>=38 degrees C, vomiting, diarrhea, headache, fatigue, muscle pain, joint pain, and use of antipyretic medications) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any(symptom present); Mild(did not interfere with activity); Moderate(some interference); Severe(prevented routine daily activity). Vomiting was scaled as: Any(vomiting present); Mild(1-2 times in 24 hours); Moderate(\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any(diarrhea present); Mild(2-3 loose stools in 24 hours); Moderate(4-5 loose stools 24 hours); Severe(\>=6 loose stools in 24 hours). Here number of participants analyzed signifies the safety population for Dose 2 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified systemic event. Participants may be represented in more than 1 category.
Time frame: Within 7 days after 13vPnC Dose 2
| Milestone | 13vPnC |
|---|---|
| Started | 158 |
| Vaccinated dose 1 | 158 |
| Vaccinated dose 2 | 146 |
| Completed | 147 |
| Not completed | 11 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Parent/legal guardian request | 2 |
| Withdrew: Failed to return | 1 |
| Milestone | 13vPnC |
|---|---|
| Started | 147 |
| Continued after 6-month fu | 89 |
| Completed | 87 |
| Not completed | 60 |
| Withdrew: Did not continue after 6-month fu | 58 |
| Withdrew: Failed to return | 2 |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 1 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 1 and after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with a determinate IgG antibody concentration for the given serotype at both 1 Month After 13vPnC Dose 1 and 1 Month After 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.
| fold rise | 13vPnC |
|---|---|
| Serotype 4 (N = 137) | 0.75 (0.66 to 0.84) |
| Serotype 6B (N = 136) | 0.89 (0.78 to 1.02) |
| Serotype 9V (N = 136) | 0.82 (0.75 to 0.91) |
| Serotype 14 (N = 137) | 0.75 (0.67 to 0.85) |
| Serotype 18C (N = 137) | 0.70 (0.62 to 0.80) |
| Serotype 19F (N = 136) | 1.05 (0.91 to 1.20) |
| Serotype 23F (N = 135) | 0.91 (0.77 to 1.08) |
| Serotype 1 (N = 137) | 0.88 (0.77 to 0.99) |
| Serotype 3 (N = 134) | 0.82 (0.75 to 0.90) |
| Serotype 5 (N = 136) | 0.90 (0.82 to 0.98) |
| Serotype 6A (N = 136) | 0.95 (0.82 to 1.10) |
| Serotype 7F (N = 137) | 0.75 (0.67 to 0.85) |
| Serotype 19A (N = 137) | 0.83 (0.74 to 0.93) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from before 13vPnC Dose 1 and 1 month after 13vPnC Dose 1 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at both the before 13vPnC Dose 1 and 1 month after 13vPnC Dose 1 blood draws. Participants may be represented in more than 1 category.
| fold rise | 13vPnC |
|---|---|
| Serotype 4 (N = 136) | 6.91 (5.27 to 9.06) |
| Serotype 6B (N = 137) | 4.72 (3.80 to 5.85) |
| Serotype 9V (N = 138) | 3.10 (2.60 to 3.70) |
| Serotype 14 (N = 138) | 5.50 (4.05 to 7.46) |
| Serotype 18C (N = 137) | 5.58 (4.47 to 6.97) |
| Serotype 19F (N = 134) | 4.76 (3.77 to 6.03) |
| Serotype 23F (N = 137) | 6.58 (5.12 to 8.46) |
| Serotype 1 (N = 129) | 3.60 (2.90 to 4.46) |
| Serotype 3 (N = 133) | 2.03 (1.78 to 2.31) |
| Serotype 5 (N = 138) | 1.74 (1.56 to 1.94) |
| Serotype 6A (N = 132) | 4.10 (3.32 to 5.05) |
| Serotype 7F (N = 137) | 4.38 (3.62 to 5.30) |
| Serotype 19A (N = 138) | 3.28 (2.73 to 3.96) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 2 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at both the before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.
| fold rise | 13vPnC |
|---|---|
| Serotype 4 (N = 137) | 1.86 (1.69 to 2.04) |
| Serotype 6B (N = 137) | 1.80 (1.60 to 2.03) |
| Serotype 9V (N = 136) | 1.48 (1.37 to 1.59) |
| Serotype 14 (N = 137) | 1.24 (1.15 to 1.35) |
| Serotype 18C (N = 137) | 1.47 (1.34 to 1.62) |
| Serotype 19F (N = 135) | 2.08 (1.85 to 2.34) |
| Serotype 23F (N = 135) | 2.04 (1.75 to 2.37) |
| Serotype 1 (N = 136) | 1.73 (1.57 to 1.92) |
| Serotype 3 (N = 133) | 1.36 (1.25 to 1.47) |
| Serotype 5 (N = 135) | 1.30 (1.22 to 1.39) |
| Serotype 6A (N = 133) | 1.80 (1.60 to 2.02) |
| Serotype 7F (N = 137) | 1.75 (1.61 to 1.90) |
| Serotype 19A (N = 137) | 1.48 (1.36 to 1.61) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were computed using the logarithmically transformed assay results for Dose 1 (after Dose 1/before Dose 1) and for Dose 2 (after Dose 2/before Dose 2). CI for the ratio of GMFR (Dose 2/Dose 1) were back transformations of a CI based on the Student t distribution for the mean logarithm of the measures (Dose 2 - Dose 1). Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for given serotype at before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.
| ratio of GMFR | 13vPnC |
|---|---|
| Serotype 4 (N = 135) | 0.26 (0.20 to 0.35) |
| Serotype 6B (N = 136) | 0.38 (0.29 to 0.49) |
| Serotype 9V (N = 136) | 0.49 (0.41 to 0.59) |
| Serotype 14 (N = 137) | 0.22 (0.16 to 0.31) |
| Serotype 18C (N = 136) | 0.26 (0.21 to 0.34) |
| Serotype 19F (N = 132) | 0.44 (0.34 to 0.57) |
| Serotype 23F (N = 135) | 0.32 (0.24 to 0.43) |
| Serotype 1 (N = 127) | 0.47 (0.37 to 0.59) |
| Serotype 3 (N = 130) | 0.66 (0.58 to 0.75) |
| Serotype 5 (N = 135) | 0.75 (0.66 to 0.85) |
| Serotype 6A (N = 127) | 0.45 (0.35 to 0.58) |
| Serotype 7F (N = 136) | 0.39 (0.32 to 0.49) |
| Serotype 19A (N = 137) | 0.45 (0.36 to 0.55) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for the specified blood draw. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at specified time point. Participants may be represented in more than 1 category.
| microgram per milliliter (mcg/mL) | 13vPnC |
|---|---|
| Before 13vPnC Dose 1: Serotype 4 (N = 136) | 1.01 (0.80 to 1.27) |
| Before 13vPnC Dose 1: Serotype 6B (N = 138) | 5.79 (4.89 to 6.87) |
| Before 13vPnC Dose 1: Serotype 9V (N = 138) | 3.01 (2.56 to 3.53) |
| Before 13vPnC Dose 1: Serotype 14 (N = 138) | 6.30 (4.78 to 8.30) |
| Before 13vPnC Dose 1: Serotype 18C (N = 137) | 1.40 (1.14 to 1.73) |
| Before 13vPnC Dose 1: Serotype 19F (N = 134) | 4.46 (3.60 to 5.53) |
| Before 13vPnC Dose 1: Serotype 23F (N = 138) | 2.80 (2.38 to 3.30) |
| Before 13vPnC Dose 1: Serotype 1 (N = 129) | 1.57 (1.26 to 1.95) |
| Before 13vPnC Dose 1: Serotype 3 (N = 133) | 1.02 (0.83 to 1.25) |
| Before 13vPnC Dose 1: Serotype 5 (N = 138) | 4.14 (3.58 to 4.78) |
| Before 13vPnC Dose 1: Serotype 6A (N = 132) | 4.62 (3.91 to 5.46) |
| Before 13vPnC Dose 1: Serotype 7F (N = 137) | 2.16 (1.80 to 2.59) |
| Before 13vPnC Dose 1: Serotype 19A (N = 138) | 8.16 (7.03 to 9.48) |
| 1 Month After 13vPnC Dose 1: Serotype 4 (N = 138) | 6.85 (5.55 to 8.44) |
| 1 Month After 13vPnC Dose 1: Serotype 6B (N= 137) | 27.25 (22.09 to 33.61) |
| 1 Month After 13vPnC Dose 1: Serotype 9V (N= 138) | 9.31 (7.83 to 11.07) |
| 1 Month After 13vPnC Dose 1: Serotype 14 (N = 138) | 34.63 (27.77 to 43.18) |
| 1 Month After 13vPnC Dose 1: Serotype 18C (N= 138) | 7.83 (6.42 to 9.54) |
| 1 Month After 13vPnC Dose 1: Serotype 19F (N= 138) | 20.40 (16.03 to 25.95) |
| 1 Month After 13vPnC Dose 1: Serotype 23F (N= 137) | 18.25 (14.52 to 22.95) |
| 1 Month After 13vPnC Dose 1: Serotype 1 (N = 138) | 5.24 (4.30 to 6.39) |
| 1 Month After 13vPnC Dose 1: Serotype 3 (N = 138) | 2.04 (1.76 to 2.38) |
| 1 Month After 13vPnC Dose 1: Serotype 5 (N = 138) | 7.19 (6.19 to 8.35) |
| 1 Month After 13vPnC Dose 1: Serotype 6A (N = 138) | 17.61 (14.16 to 21.91) |
| 1 Month After 13vPnC Dose 1: Serotype 7F (N = 138) | 9.46 (8.17 to 10.94) |
| 1 Month After 13vPnC Dose 1: Serotype 19A (N= 138) | 26.82 (22.16 to 32.46) |
| Before 13vPnC Dose 2: Serotype 4 (N = 138) | 2.77 (2.29 to 3.35) |
| Before 13vPnC Dose 2: Serotype 6B (N = 138) | 13.67 (11.23 to 16.63) |
| Before 13vPnC Dose 2: Serotype 9V (N = 138) | 5.19 (4.41 to 6.09) |
| Before 13vPnC Dose 2: Serotype 14 (N = 138) | 21.07 (17.29 to 25.67) |
| Before 13vPnC Dose 2: Serotype 18C (N = 138) | 3.73 (3.10 to 4.49) |
| Before 13vPnC Dose 2: Serotype 19F (N = 137) | 10.34 (8.32 to 12.85) |
| Before 13vPnC Dose 2: Serotype 23F (N = 137) | 8.07 (6.63 to 9.83) |
| Before 13vPnC Dose 2: Serotype 1 (N = 137) | 2.65 (2.21 to 3.19) |
| Before 13vPnC Dose 2: Serotype 3 (N = 135) | 1.27 (1.06 to 1.52) |
| Before 13vPnC Dose 2: Serotype 5 (N = 137) | 4.91 (4.26 to 5.66) |
| Before 13vPnC Dose 2: Serotype 6A (N = 135) | 9.05 (7.48 to 10.95) |
| Before 13vPnC Dose 2: Serotype 7F (N = 138) | 4.09 (3.52 to 4.74) |
| Before 13vPnC Dose 2: Serotype 19A (N = 138) | 15.13 (12.73 to 17.98) |
| 1 Month After 13vPnC Dose 2: Serotype 4 (N = 137) | 5.09 (4.28 to 6.04) |
| 1 Month After 13vPnC Dose 2: Serotype 6B (N= 137) | 24.52 (20.48 to 29.35) |
| 1 Month After 13vPnC Dose 2: Serotype 9V (N= 136) | 7.46 (6.46 to 8.61) |
| 1 Month After 13vPnC Dose 2: Serotype 14 (N = 137) | 26.19 (22.11 to 31.03) |
| 1 Month After 13vPnC Dose 2: Serotype 18C (N= 137) | 5.44 (4.64 to 6.38) |
| 1 Month After 13vPnC Dose 2: Serotype 19F (N= 136) | 20.56 (17.15 to 24.63) |
| 1 Month After 13vPnC Dose 2: Serotype 23F (N= 135) | 16.18 (13.27 to 19.73) |
| 1 Month After 13vPnC Dose 2: Serotype 1 (N = 137) | 4.51 (3.82 to 5.32) |
| 1 Month After 13vPnC Dose 2: Serotype 3 (N = 134) | 1.67 (1.42 to 1.97) |
| 1 Month After 13vPnC Dose 2: Serotype 5 (N = 136) | 6.33 (5.58 to 7.17) |
| 1 Month After 13vPnC Dose 2: Serotype 6A (N = 136) | 16.37 (13.65 to 19.64) |
| 1 Month After 13vPnC Dose 2: Serotype 7F (N = 137) | 7.06 (6.20 to 8.04) |
| 1 Month After 13vPnC Dose 2: Serotype 19A (N= 137) | 22.19 (18.94 to 25.99) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for the specified blood draw. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here number of participants analyzed signifies the evaluable immunogenicity population at 1-year follow-up and "N" signifies participants with determinate IgG antibody concentration for the given serotype. Participants may be represented in more than 1 category.
| mcg/mL | 13vPnC |
|---|---|
| Serotype 4 (N = 81) | 1.94 (1.51 to 2.48) |
| Serotype 6B (N = 81) | 11.77 (9.43 to 14.71) |
| Serotype 9V (N = 81) | 4.50 (3.61 to 5.62) |
| Serotype 14 (N = 81) | 15.89 (12.47 to 20.26) |
| Serotype 18C (N = 81) | 2.64 (2.03 to 3.42) |
| Serotype 19F (N = 81) | 9.87 (7.50 to 13.00) |
| Serotype 23F (N = 81) | 7.70 (6.15 to 9.63) |
| Serotype 1 (N = 79) | 2.12 (1.65 to 2.71) |
| Serotype 3 (N = 67) | 1.01 (0.77 to 1.33) |
| Serotype 5 (N = 81) | 4.38 (3.58 to 5.37) |
| Serotype 6A (N = 81) | 7.94 (6.45 to 9.77) |
| Serotype 7F (N = 81) | 3.47 (2.84 to 4.25) |
| Serotype 19A (N = 81) | 13.30 (10.62 to 16.65) |
Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMT and corresponding 2-sided 95% CIs were evaluated. CIs for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate OPA antibody titer for the given serotype at specified time point. Participants may be represented in more than 1 category.
| titer | 13vPnC |
|---|---|
| Before 13vPnC Dose 1: Serotype 4 (N = 105) | 215 (129.6 to 357.2) |
| Before 13vPnC Dose 1: Serotype 6B (N = 105) | 626 (377.5 to 1037.4) |
| Before 13vPnC Dose 1: Serotype 9V (N = 109) | 234 (137.6 to 398.7) |
| Before 13vPnC Dose 1: Serotype 14 (N = 115) | 628 (425.8 to 925.7) |
| Before 13vPnC Dose 1: Serotype 18C (N = 95) | 426 (235.7 to 771.4) |
| Before 13vPnC Dose 1: Serotype 19F (N = 96) | 94 (55.0 to 160.7) |
| Before 13vPnC Dose 1: Serotype 23F (N = 106) | 34 (21.5 to 54.8) |
| Before 13vPnC Dose 1: Serotype 1 (N = 131) | 7 (5.7 to 8.8) |
| Before 13vPnC Dose 1: Serotype 3 (N = 107) | 13 (10.1 to 17.5) |
| Before 13vPnC Dose 1: Serotype 5 (N = 131) | 10 (7.8 to 13.9) |
| Before 13vPnC Dose 1: Serotype 6A (N = 116) | 246 (149.0 to 404.8) |
| Before 13vPnC Dose 1: Serotype 7F (N = 120) | 344 (220.5 to 537.9) |
| Before 13vPnC Dose 1: Serotype 19A (N = 127) | 137 (100.0 to 187.4) |
| 1 Month After 13vPnC Dose 1: Serotype 4 (N = 108) | 2670 (2128.1 to 3351.1) |
| 1 Month After 13vPnC Dose 1: Serotype 6B (N= 116) | 7535 (6320.5 to 8983.5) |
| 1 Month After 13vPnC Dose 1: Serotype 9V (N= 103) | 2312 (1684.0 to 3172.8) |
| 1 Month After 13vPnC Dose 1: Serotype 14 (N = 117) | 2288 (1906.6 to 2745.0) |
| 1 Month After 13vPnC Dose 1: Serotype 18C (N= 103) | 4326 (3250.3 to 5756.8) |
| 1 Month After 13vPnC Dose 1: Serotype 19F (N = 89) | 1429 (1043.5 to 1957.3) |
| 1 Month After 13vPnC Dose 1: Serotype 23F (N= 106) | 1607 (1227.4 to 2102.7) |
| 1 Month After 13vPnC Dose 1: Serotype 1 (N = 123) | 56 (41.0 to 77.4) |
| 1 Month After 13vPnC Dose 1: Serotype 3 (N = 112) | 115 (93.0 to 142.1) |
| 1 Month After 13vPnC Dose 1: Serotype 5 (N = 121) | 277 (198.4 to 385.8) |
| 1 Month After 13vPnC Dose 1: Serotype 6A (N = 117) | 7845 (6581.6 to 9349.9) |
| 1 Month After 13vPnC Dose 1: Serotype 7F (N = 123) | 3348 (2881.9 to 3888.5) |
| 1 Month After 13vPnC Dose 1: Serotype 19A (N =118) | 1449 (1164.2 to 1804.3) |
| Before 13vPnC Dose 2: Serotype 4 (N = 104) | 1331 (1013.9 to 1748.1) |
| Before 13vPnC Dose 2: Serotype 6B (N = 108) | 4174 (3513.0 to 4958.3) |
| Before 13vPnC Dose 2: Serotype 9V (N = 99) | 1445 (1051.7 to 1985.5) |
| Before 13vPnC Dose 2: Serotype 14 (N = 106) | 1652 (1347.8 to 2024.1) |
| Before 13vPnC Dose 2: Serotype 18C (N = 101) | 1928 (1281.1 to 2901.0) |
| Before 13vPnC Dose 2: Serotype 19F (N = 92) | 516 (338.8 to 785.5) |
| Before 13vPnC Dose 2: Serotype 23F (N = 94) | 897 (619.0 to 1300.4) |
| Before 13vPnC Dose 2: Serotype 1 (N = 107) | 23 (17.1 to 32.3) |
| Before 13vPnC Dose 2: Serotype 3 (N = 120) | 56 (45.5 to 69.9) |
| Before 13vPnC Dose 2: Serotype 5 (N = 107) | 98 (69.2 to 140.2) |
| Before 13vPnC Dose 2: Serotype 6A (N = 113) | 4005 (3350.6 to 4786.3) |
| Before 13vPnC Dose 2: Serotype 7F (N = 112) | 1791 (1427.0 to 2248.6) |
| Before 13vPnC Dose 2: Serotype 19A (N = 108) | 677 (544.4 to 843.1) |
| 1 Month After 13vPnC Dose 2: Serotype 4 (N = 105) | 3051 (2536.7 to 3670.3) |
| 1 Month After 13vPnC Dose 2: Serotype 6B (N= 107) | 7601 (6392.6 to 9038.6) |
| 1 Month After 13vPnC Dose 2: Serotype 9V (N = 96) | 3467 (2784.0 to 4317.6) |
| 1 Month After 13vPnC Dose 2: Serotype 14 (N = 110) | 2081 (1770.5 to 2446.0) |
| 1 Month After 13vPnC Dose 2: Serotype 18C (N= 103) | 5271 (4267.8 to 6510.1) |
| 1 Month After 13vPnC Dose 2: Serotype 19F (N = 89) | 1507 (1139.9 to 1992.2) |
| 1 Month After 13vPnC Dose 2: Serotype 23F (N= 105) | 2330 (1880.4 to 2887.0) |
| 1 Month After 13vPnC Dose 2: Serotype 1 (N = 106) | 78 (59.5 to 101.2) |
| 1 Month After 13vPnC Dose 2: Serotype 3 (N = 109) | 105 (87.2 to 127.2) |
| 1 Month After 13vPnC Dose 2: Serotype 5 (N = 118) | 273 (213.9 to 349.2) |
| 1 Month After 13vPnC Dose 2: Serotype 6A (N = 111) | 7633 (6439.6 to 9048.6) |
| 1 Month After 13vPnC Dose 2: Serotype 7F (N = 114) | 3723 (3276.2 to 4230.1) |
| 1 Month After 13vPnC Dose 2: Serotype 19A (N= 115) | 1314 (1084.4 to 1592.6) |
Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMT and corresponding 2-sided 95% CIs were evaluated. CIs for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here number of participants analyzed signifies the evaluable immunogenicity population at 1-year follow-up and "N" signifies participants with determinate OPA antibody titer for the given serotype. Participants may be represented in more than 1 category.
| titer | 13vPnC |
|---|---|
| Serotype 4 (N = 58) | 1107 (764.4 to 1602.2) |
| Serotype 6B (N = 59) | 3412 (2746.4 to 4238.7) |
| Serotype 9V (N = 66) | 1690 (1157.8 to 2465.5) |
| Serotype 14 (N = 64) | 1595 (1281.6 to 1984.9) |
| Serotype 18C (N = 59) | 1604 (1107.2 to 2324.2) |
| Serotype 19F (N = 55) | 620 (376.6 to 1020.4) |
| Serotype 23F (N = 58) | 924 (654.2 to 1306.1) |
| Serotype 1 (N = 73) | 25 (17.5 to 35.4) |
| Serotype 3 (N = 72) | 31 (22.6 to 42.6) |
| Serotype 5 (N = 71) | 102 (70.5 to 148.0) |
| Serotype 6A (N = 72) | 2485 (1921.2 to 3214.3) |
| Serotype 7F (N = 73) | 2166 (1861.4 to 2519.3) |
| Serotype 19A (N = 73) | 589 (449.4 to 771.1) |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as: Any (redness present or swelling present); Mild (less than \<2.5 centimeters \[cm\] for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged greater than or equal to \[\>=\] 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>=12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>=12 years). Pain was scaled as: Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Here "Number of participants analyzed" signifies the safety population for Dose 1 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified local reaction. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC |
|---|---|
| Pain: Any (N = 144) | 89.6 |
| Pain: Mild (N = 132) | 81.8 |
| Pain: Moderate (N = 113) | 56.6 |
| Pain: Severe (N = 90) | 11.1 |
| Redness: Any (N = 93) | 23.7 |
| Redness: Mild (N = 93) | 20.4 |
| Redness: Moderate (N = 90) | 8.9 |
| Redness: Severe (N = 87) | 1.1 |
| Swelling: Any (N = 108) | 49.1 |
| Swelling: Mild (N = 101) | 37.6 |
| Swelling: Moderate (N = 100) | 26.0 |
| Swelling: Severe (N = 87) | 1.1 |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as: Any (redness present or swelling present); Mild (\<2.5 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>=12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>=12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>=12 years). Pain was scaled as: Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Here number of participants analyzed signifies the safety population for Dose 2 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified local reaction. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC |
|---|---|
| Pain: Any (N = 111) | 85.6 |
| Pain: Mild (N = 103) | 77.7 |
| Pain: Moderate (N = 82) | 53.7 |
| Pain: Severe (N = 69) | 15.9 |
| Redness: Any (N = 67) | 26.9 |
| Redness: Mild (N = 66) | 15.2 |
| Redness: Moderate (N = 64) | 14.1 |
| Redness: Severe (N = 63) | 0.0 |
| Swelling: Any (N = 84) | 53.6 |
| Swelling: Mild (N = 77) | 37.7 |
| Swelling: Moderate (N = 73) | 35.6 |
| Swelling: Severe (N = 63) | 0.0 |
Specific systemic events (fever \>=38 degrees Celsius\[C\], vomiting, diarrhea, headache, fatigue, muscle pain, joint pain, use of antipyretic medications) were prompted for each day and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any(symptom present); Mild(did not interfere with activity); Moderate(some interference); Severe(prevented routine daily activity). Vomiting was scaled as: Any(vomiting present); Mild(1-2 times in 24 hours); Moderate(\>2 times in 24 hours); Severe(required intravenous hydration). Diarrhea was scaled as: Any(diarrhea present); Mild(2-3 loose stools in 24 hours);Moderate(4-5 loose stools 24 hours); Severe(\>=6 loose stools in 24 hours). Here number of participants analyzed signifies the safety population for Dose 1 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified systemic event. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC |
|---|---|
| Fever: >=38, =<38.4 degrees C (N = 81) | 13.6 |
| Fever: >38.4, =<38.9 degrees C (N = 82) | 7.3 |
| Fever: >38.9, =<40 degrees C (N = 79) | 3.8 |
| Fever: >40 degrees C (N = 79) | 1.3 |
| Vomiting: Any (N = 91) | 15.4 |
| Vomiting: Mild (N = 89) | 11.2 |
| Vomiting: Moderate (N = 90) | 6.7 |
| Vomiting: Severe (N = 87) | 0.0 |
| Diarrhea: Any (N = 90) | 13.3 |
| Diarrhea: Mild (N = 87) | 6.9 |
| Diarrhea: Moderate (N = 90) | 6.7 |
| Diarrhea: Severe (N = 87) | 2.3 |
| Headache: Any (N = 110) | 53.6 |
| Headache: Mild (N = 105) | 42.9 |
| Headache: Moderate (N = 101) | 34.7 |
| Headache: Severe (N = 92) | 12.0 |
| Fatigue: Any (N = 118) | 66.1 |
| Fatigue: Mild (N = 108) | 48.1 |
| Fatigue: Moderate (N = 104) | 44.2 |
| Fatigue: Severe (N = 90) | 14.4 |
| Muscle Pain: Any (N = 127) | 74.8 |
| Muscle Pain: Mild (N = 114) | 58.8 |
| Muscle Pain: Moderate (N = 108) | 47.2 |
| Muscle Pain: Severe (N = 89) | 10.1 |
| Joint Pain: Any (N = 103) | 39.8 |
| Joint Pain: Mild (N = 98) | 23.5 |
| Joint Pain: Moderate (N = 94) | 23.4 |
| Joint Pain: Severe (N = 89) | 4.5 |
| Use of Antipyretic Medications (N = 110) | 58.2 |
Specific systemic events (fever \>=38 degrees C, vomiting, diarrhea, headache, fatigue, muscle pain, joint pain, and use of antipyretic medications) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any(symptom present); Mild(did not interfere with activity); Moderate(some interference); Severe(prevented routine daily activity). Vomiting was scaled as: Any(vomiting present); Mild(1-2 times in 24 hours); Moderate(\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any(diarrhea present); Mild(2-3 loose stools in 24 hours); Moderate(4-5 loose stools 24 hours); Severe(\>=6 loose stools in 24 hours). Here number of participants analyzed signifies the safety population for Dose 2 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified systemic event. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC |
|---|---|
| Fever: >=38, =<38.4 degrees C (N = 63) | 9.5 |
| Fever: >38.4, =<38.9 degrees C (N = 59) | 6.8 |
| Fever: >38.9, =<40 degrees C (N = 63) | 6.3 |
| Fever: >40 degrees C (N = 60) | 1.7 |
| Vomiting: Any (N = 67) | 13.4 |
| Vomiting: Mild (N = 65) | 9.2 |
| Vomiting: Moderate (N = 64) | 4.7 |
| Vomiting: Severe (N = 64) | 1.6 |
| Diarrhea: Any (N = 68) | 25.0 |
| Diarrhea: Mild (N = 68) | 19.1 |
| Diarrhea: Moderate (N = 66) | 12.1 |
| Diarrhea: Severe (N = 63) | 3.2 |
| Headache: Any (N = 86) | 59.3 |
| Headache: Mild (N = 74) | 41.9 |
| Headache: Moderate (N = 76) | 36.8 |
| Headache: Severe (N = 66) | 10.6 |
| Fatigue: Any (N = 96) | 62.5 |
| Fatigue: Mild (N = 84) | 48.8 |
| Fatigue: Moderate (N = 83) | 41.0 |
| Fatigue: Severe (N = 67) | 13.4 |
| Muscle Pain: Any (N = 98) | 75.5 |
| Muscle Pain: Mild (N = 87) | 60.9 |
| Muscle Pain: Moderate (N = 84) | 45.2 |
| Muscle Pain: Severe (N = 67) | 16.4 |
| Joint Pain: Any (N = 78) | 44.9 |
| Joint Pain: Mild (N = 72) | 34.7 |
| Joint Pain: Moderate (N = 70) | 21.4 |
| Joint Pain: Severe (N = 65) | 6.2 |
| Use of Antipyretic Medications (N = 78) | 43.6 |
Collected over SAEs: 13vPnC Dose 1 through 1-year follow-up after 13vPnC Dose 2. AEs: 13vPnC Dose 1; 13vPnC Dose 2; 6-month follow-up after 13vPnC Dose 2; 1-year follow-up after 13vPnC Dose 2. Local reactions/systemic events: within 7 days after 13vPnC Dose 1 and Dose 2. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Dose 1 | — | 40/158 (25.3%) | 133/158 (84.2%) |
| 13vPnC Dose 2 | — | 11/140 (7.9%) | 100/140 (71.4%) |
| 6-Month Follow-up | — | 28/147 (19%) | 1/147 (0.7%) |
| 1-Year Follow-up | — | 16/87 (18.4%) | 1/87 (1.1%) |
| Event | 13vPnC Dose 1 | 13vPnC Dose 2 | 6-Month Follow-up | 1-Year Follow-up |
|---|---|---|---|---|
| Sickle cell anaemia with crisisCongenital, familial and genetic disorders | 22/158 | 5/140 | 17/147 | 11/87 |
| PneumoniaInfections and infestations | 1/158 | 0/140 | 2/147 | 4/87 |
| PyrexiaGeneral disorders | 5/158 | 0/140 | 2/147 | 3/87 |
| Acute chest syndromeRespiratory, thoracic and mediastinal disorders | 3/158 | 0/140 | 2/147 | 1/87 |
| Vascular occlusionVascular disorders | 3/158 | 2/140 | 0/147 | 0/87 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/158 | 2/140 | 0/147 | 0/87 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/158 | 2/140 | 0/147 | 0/87 |
| PainGeneral disorders | 1/158 | 0/140 | 2/147 | 1/87 |
| Upper respiratory tract infectionInfections and infestations | 2/158 | 0/140 | 0/147 | 0/87 |
| Back painMusculoskeletal and connective tissue disorders | 2/158 | 0/140 | 1/147 | 0/87 |
| Event | 13vPnC Dose 1 | 13vPnC Dose 2 | 6-Month Follow-up | 1-Year Follow-up |
|---|---|---|---|---|
| Pain (Any)Skin and subcutaneous tissue disorders | 129/144 | 95/111 | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | 108/132 | 80/103 | — | — |
| Muscle pain (Any)General disorders | 95/127 | 74/98 | — | — |
| Fatigue (Any)General disorders | 78/118 | 60/96 | — | — |
| Muscle pain (Mild)General disorders | 67/114 | 53/87 | — | — |
| Headache (Any)General disorders | 59/110 | 51/86 | — | — |
| Pain (Moderate)Skin and subcutaneous tissue disorders | 64/113 | 44/82 | — | — |
| Swelling (Any)Skin and subcutaneous tissue disorders | 53/108 | 45/84 | — | — |
| Fatigue (Mild)General disorders | 52/108 | 41/84 | — | — |
| Muscle pain (Moderate)General disorders | 51/108 | 38/84 | — | — |
All-available immunogenicity (AAI) population included all participants who had at least 1 valid and determinate pneumococcal assay result for the planned analysis.
| Age, Continuous(years) | 13vPnC |
|---|---|
| Mean | 13.3 ± 3.08 |
| Sex: Female, Male(Participants) | 13vPnC |
|---|---|
| Female | 76 |
| Male | 82 |
The record gives a start of Nov 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine